Incyte (INCY) Tops Q3 EPS by 21c; Raises Jakafi Revenue Outlook

November 1, 2016 7:03 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Incyte (NASDAQ: INCY) reported Q3 EPS of $0.20, $0.21 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $269.47 million versus the consensus estimate of $261.43 million.

$224 million of 2016 third-quarter net product revenues from Jakafi® (ruxolitinib), representing 39 percent growth over the same period last year

“Incyte continues to deliver dynamic sales growth from Jakafi in the U.S. and now from Iclusig in Europe. With a potential additional future source of revenue from baricitinib, we are able to make significant investments in opportunities across our broad and diverse clinical portfolio,” stated Hervé Hoppenot, Incyte’s Chief Executive Officer. “Our commercial footprint has expanded to include Europe in addition to the U.S., and as our portfolio matures, we are in an excellent position to build Incyte into a world-class biopharmaceutical organization.”

2016 Financial Guidance

The Company has updated its full year 2016 financial guidance, as detailed below.

Current

Previous

Jakafi net product revenues

$850-$855 million $825-$835 million

Iclusig net product revenues

$25-$30 million Unchanged

Research and development expenses

$570-$580 million $620-$630 million

Selling, general and administrative expenses

$285-$310 million Unchanged

Change in fair value of acquisition-related contingent consideration

$17 million Unchanged

For earnings history and earnings-related data on Incyte (INCY) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings, Guidance, Management Comments

Related Entities

Earnings, Definitive Agreement

Add Your Comment